{"url_path":"/sec/cik-0001567892/8-k/2026-08-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1567892/0001628280-26-055477-index.html","accession_number":"0001628280-26-055477","cik":"0001567892","ticker":null,"issuer_name":"Keenova Therapeutics plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1567892/0001628280-26-055477-index.html","primary_entity_key":"0001567892","primary_entity_name":"Keenova Therapeutics plc"},"word_count":76,"has_tables":true,"body_markdown":"Item 9.01    Financial Statements and Exhibits.\n\n(d) Exhibits\n\nExhibit NumberExhibit\n\n99.1\n[Second Quarter Financial Results.](a20260630keenovaex991q2202.htm)\n\n104Cover Page Interactive Data File (embedded within the inline XBRL document).\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nKEENOVA THERAPEUTICS PLC\n\n(registrant)\n\nDate:August 11, 2026By:/s/ Christiana Stamoulis\n\nChristiana Stamoulis\n\nPresident and Chief Financial Officer\n\n(principal financial officer)"}